In vivo local administration of osteogenic protein-1 increases structural properties of the overstretched anterior cruciate ligament with partial midsubstance laceration: a biomechanical study in rabbits.
We report the effects of local administration of osteogenic protein-1 on the biomechanical properties of the overstretched anterior cruciate ligament in an animal model. An injury in the anterior cruciate ligament was created in 45 rabbits. They were divided into three equal groups. In group 1, no treatment was applied, in group II, phosphate-buffered saline was applied around the injured ligament, and in group III, 12.5 microg of osteogenic protein-1 mixed with phosphate-buffered saline was applied around the injured ligament. A control group of 15 rabbits was assembled from randomly-selected injured knees from among the first three groups. Each rabbit was killed at 12 weeks. The maximum load and stiffness of the anterior cruciate ligament was found to be significantly greater in group III than either group 1 (p = 0.002, p = 0.014) or group II (p = 0.032, p = 0.025). The tensile strength and the tangent modulus of fascicles from the ligament were also significantly greater in group III than either group I (p = 0.002, p = 0.0174) or II (p = 0.005, p = 0.022). The application of osteogenic protein-1 enhanced the healing in the injured anterior cruciate ligament, but compared with the control group the treated ligament remained lengthened. The administration of osteogenic protein-1 may have a therapeutic role in treating the overstretched anterior cruciate ligament.
Hayashi
R
R
Department of Orthopaedic Surgery, Yokohama City University School of Medicine, Fukuura 3-9, Kanazawa-ku, Yokohama City, Kanagawa Prefecture, 236-0004, Japan.
Kondo
E
E
Tohyama
H
H
Saito
T
T
Yasuda
K
K
D000818:Animals; D016118:Anterior Cruciate Ligament / Q000187:drug effects; D000070598:Anterior Cruciate Ligament Injuries; D001696:Biomechanical Phenomena; D055419:Bone Morphogenetic Protein 7; D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage*; D005260:Female; D022125:Lacerations / Q000188:drug therapy*; D011817:Rabbits; D013314:Stress, Mechanical; D013718:Tensile Strength / Q000187:drug effects / Q000502:physiology; D016212:Transforming Growth Factor beta / Q000008:administration & dosage*; D014945:Wound Healing / Q000187:drug effects*
D055419:Bone Morphogenetic Protein 7; D019485:Bone Morphogenetic Proteins; D016212:Transforming Growth Factor beta